Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

Importance Efficacy of cannabidiol has been demonstrated in seizures associated with
Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in …

Novel and effective antiseizure medications are needed to treat refractory and rare forms of
epilepsy. Cannabinoids, which are obtained from the cannabis plant, have a long history of …

Dravet syndrome is a severe developmental and epileptic encephalopathy characterised by
refractory seizures and cognitive dysfunction. The treatment is challenging, not least …

Objective To evaluate the long‐term safety and efficacy of add‐on cannabidiol (CBD) in
patients with seizures associated with tuberous sclerosis complex (TSC) in the open‐label …

Summary Cannabidiol (CBD), a non-euphoric component of cannabis, reduces seizures in
multiple forms of pediatric epilepsies, but the mechanism (s) of anti-seizure action remain …

Summary Objective Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is
often treatment resistant. Efficacy and safety of add‐on cannabidiol (CBD) to treat seizures …

The therapeutic potential of cannabidiol (CBD) in seizure disorders has been known for
many years, but it is only in the last decade that major progress has been made in …

Objective To evaluate the potential impact of concomitant clobazam (CLB) use on the
efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome and Lennox …